The medtech sector already is feeling the effect of the 2.3% excise tax ahead of its implementation in 2013 as shown by recent reports on companies planning to cut jobs and move production overseas. Accoding to a column originally published by Bloomberg.com, aside from potentially eliminating more than 45,000 jobs, the tax also could reduce funding in research and development, thereby hurting innovation.

The column can be accessed on Bloomberg.com's website.